Depemokimab is an anti-interleukin-5 agent that can be administered every six months, offering a less frequent dosing alternative.
In a phase 3 study, 629 patients 12 and older participated, including 419 who had previously received depemokimab and 210 who had taken a placebo in an earlier trial.
After 52 weeks of treatment, annualized exacerbation rates were 0.46 for those who had previously used depemokimab and 0.48 for those transitioning from a placebo. Overall, 72% of patients were exacerbation free and 96% did not require hospitalization or emergency department visits.
GSK has submitted depemokimab for FDA approval.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
